FDA lifts clin­i­cal hold on Mer­sana’s STING ag­o­nist, PhI start­ing dose low­ered af­ter pa­tient death

The FDA has lift­ed the full clin­i­cal hold on Mer­sana Ther­a­peu­tics’ STING-tar­get­ed an­ti­body-drug con­ju­gate on the back of the com­pa­ny mak­ing Phase I study dos­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER